Tesamorelin
Tesamorelin discontinuation and continuing benefit
The reduction in fat around organs was sustained during continued treatment. The return after discontinuation changes what a lasting solution can mean.
The return of visceral fat
The 52-week tesamorelin program in adults with HIV supplies the finding around which this site turns. Visceral-fat reduction was sustained at -18% over 52 weeks during continued treatment. Visceral fat reaccumulated when treatment stopped. Glucose changes over that interval were judged not clinically significant.
I value the way discontinuation complicates the success. The treatment had an observable effect, and the benefit depended on continued treatment. A return after discontinuation leaves a different decision from a benefit that lasts after the intervention ends.
The program reported 273 participants receiving tesamorelin and 137 receiving placebo. Its patients had excess abdominal fat in the setting of HIV. The result concerns a particular fat compartment and patient group.
The -18% figure compares with baseline during continued treatment. It does not describe a permanent reduction after discontinuation.
Visceral-fat area; hepatic-fat proportion
The six-month randomized JAMA trial enrolled 50 adults receiving antiretroviral treatment: 28 received tesamorelin and 22 placebo. The treatment effect on visceral-fat area was -42 square centimeters. The net treatment effect on hepatic lipid-to-water percentage, the liver-fat measurement in that study, was -2.9% compared with placebo.
Different measurements sit behind those figures. An area on an abdominal scan and a liver-fat proportion each say something specific about where fat changed; neither is a total-body weight-loss percentage.
The 2026 meta-analysis of five randomized trials found an average difference in visceral-fat area of -27.71 square centimeters, with a 95% confidence interval of -38.37 to -17.06. The interval expresses uncertainty around the pooled average treatment difference. It does not describe the range of individual patients’ changes. The review also found reduced hepatic fat and increased lean body mass.
I trust a result more comfortably when I can picture what the instrument measured. Here the papers give a concrete target, alongside limits on the patients to whom the finding applies.
The two-week hormone experiment
Tesamorelin mimics the body’s growth hormone-releasing hormone, with a chemical modification that slows breakdown. It stimulates the pituitary to release the body’s own growth hormone; IGF-1 rises downstream.
A two-week study in thirteen healthy men found mean overnight growth hormone increased by +0.5 micrograms per liter and IGF-1 increased by 181 micrograms per liter. Neither fasting glucose nor insulin-stimulated glucose uptake changed significantly during that brief test.
The distinction between a hormone measurement and a fat measurement is useful here. This study addressed the hormonal and metabolic response over a short interval. The larger fat studies asked other questions in adults with HIV. I give each experiment the job it actually undertook.
The approved use and the safety limits
Tesamorelin’s United States approval dates to 2010 and covers reducing excess abdominal fat in adults with HIV-associated lipodystrophy. General weight loss, anti-aging, memory enhancement and fatty liver without HIV remain outside that approval. A shared hormone target gives CJC-1295 no claim to tesamorelin’s clinical results.
The pooled trial review reported no serious adverse events or glucose perturbation. The longer study’s 52-week glucose findings were not clinically significant. Those observations have a defined follow-up interval; longer-term cancer safety remains limited, and active malignancy is a labeled contraindication. Raising IGF-1 creates concern about stimulating existing tumors. Blood-sugar changes can occur and remain relevant when glucose regulation is already impaired.
The LiverTox assessment rates clinically apparent liver injury unlikely, with no attributable cases reported in that review. That is a liver-safety assessment, with a different scope from the broader cancer and metabolic questions.
The evidence describes specific patients, a maintained benefit and continuing safety questions. Research-grade material lacks the approved product’s purity and potency oversight. WADA prohibits tesamorelin in sport at all times.